When was 28bio founded?

28bio was founded in 2014 and raised its 1st funding round 11 years after it was founded.

Where is 28bio located?

28bio is headquartered in New Orleans, United States.

How many employees does 28bio have?

As of Aug 31, 2026, the latest employee count at 28bio is 26.

Is 28bio a funded company?

28bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on May 21, 2025.

When was the latest funding round of 28bio?

28bio's latest funding was a $***** Series A round on May 21, 2025, with participation from 0 investor.

Where does 28bio rank among its competitors?

28bio ranks 4th amongst 7 active competitors, of which 2 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was 28bio, which secured $6.52M in May, 2025.

Who are the top competitors of 28bio?

28bio's top competitors include MycoMedica, AGADA Biosciences and NeuroSolutions. Among them, 28bio secured the most recent funding round in May, 2025.

28bio - 2026 Company Profile, Funding & Competitors

Company Details

Developer of human neural organoid models for drug testing applications. These models assess functional synaptic plasticity and evaluate remyelinating drug efficacy by quantifying myelin loss, recovery, and repair. Services facilitate preclinical drug development by measuring human neural activity linked to clinical safety and efficacy. Technologies include central and peripheral nervous system models used to predict patient response to small molecules.

Key Metrics

Founded Year

2014

Location

New Orleans, United States

Stage

Series A

Total Funding

$6.52M in 1 round

Latest Funding Round

Series A, May 21, 2025, $*****

Investors

Granpool

Ranked

4^th among 7 active competitors

Employee Count

26 as on Aug 31, 2026

Similar Companies

MycoMedica & 6 more

View 28bio's full profile

28bio has raised a total funding of $6.52M over 1 round. 28bio has 1 institutional investor.

Here is the list of recent funding rounds of 28bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 21, 2025	3012946	Series A	3872644	7486644	2791207	6143001

Access funding benchmarks and valuations. Sign up today!

View details of 28bio's funding rounds and investors

28bio's employee count trend

28bio has 26 employees as of Aug 26. Here is 28bio's employee count trend over the years:

Uncover 28bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of 28bio include MycoMedica, AGADA Biosciences and NeuroSolutions. Here is the list of Top 10 competitors of 28bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MycoMedica 2021, Orange (United States), Series A	Life sciences company focused on developing therapeutic drugs derived from fungi to help prevent and treat psychiatric and neurological disorders	$60M	Obvious Ventures, True Ventures & 3 others	33/100
2nd	AGADA Biosciences 2013, Halifax (Canada), Funding Raised	Drug development program expert specializing in neuromuscular diseases	-	Invest Nova Scotia	32/100
3rd	NeuroSolutions 2001, Coventry (United Kingdom), Unfunded	Provider of preclinical neuroscience research services	-	-	27/100
4th	28bio 2014, New Orleans (United States), Series A	Developer of human neural organoid models for drug testing applications	$6.52M	Granpool	25/100
5th	Phenotype Expertise 2013, Marseille (France), Unfunded	Provider of preclinical services offering drug evaluation and behavioral analysis solutions in mice and rats	-	-	24/100
6th	NeuroProof 2007, Rostock (Germany), Funding Raised	Provider of preclinical services offering specialized phenotypic screening services for neuro-pharmaceuticals	-	Sobera Capital	22/100
7th	Translational Neurometrics 2024, Bayreuth (Germany), Unfunded	CRO specializing in preclinical neuroscience, leveraging advanced in vivo neurotechnology to support the development of innovative treatments	-	-	16/100
8th	Neuroscience Technologies 2005, Barcelona (Spain), Deadpooled	Provider of pre-clincial discovery and development	-	Ventac Partners	14/100